4-thiophen-2-ylmethyl-1,3-dihydro-imidazole-2-thione | 880652-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 4-thiophen-2-ylmethyl-1,3-dihydro-imidazole-2-thione
• 英文别名: 4-(Thiophen-2-ylmethyl)-1,3-dihydroimidazole-2-thione
• CAS: 880652-76-6
• 化学式: C₈H₈N₂S₂
• 分子量: 196.297
• InChiKey: VPSLOKRFODRORN-UHFFFAOYSA-N

物化性质

• 沸点：
  319.6±44.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.4
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
  申请人：Heidelbaugh M. Todd

  公开号：US20060069143A1

  公开（公告）日：2006-03-30

  Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha 2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha 2B and/or alpha 2C adrenergic receptors in preference over alpha 2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.

  式1的化合物，其中变量的含义在规范中定义，是α2肾上腺素受体的激动剂。本公开的几种化合物对α2B和/或alpha2C肾上腺素受体具有特异性或选择性，而不是alpha2A肾上腺素受体。此外，一些声明的化合物没有或仅有最小的心血管和/或镇静作用。式1的化合物可用作哺乳动物，包括人类，治疗对α2肾上腺素受体激动剂治疗有反应的疾病和/或缓解条件的药物。具有无显著心血管和/或镇静作用的式1的化合物可用于治疗疼痛和其他具有最小副作用的疾病。
• 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS
  申请人：Heidelbaugh Todd M.

  公开号：US20080221152A1

  公开（公告）日：2008-09-11

  Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha 2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha 2B and/or alpha 2C adrenergic receptors in preference over alpha 2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardiovascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.

  公式1的化合物，其中变量的含义在说明书中定义，是α2肾上腺素受体的激动剂。本公开的几种化合物对α2B和/或α2C肾上腺素受体具有特异性或选择性，而不是α2A肾上腺素受体。此外，一些声明的化合物没有或只有最小的心血管和/或镇静活性。公式1的化合物在哺乳动物中，包括人类，用于治疗对α2肾上腺素受体激动剂有反应的疾病和/或缓解条件，是有用的药物。具有无显著心血管和/或镇静活性的公式1的化合物可用于治疗疼痛和其他具有最小副作用的病症。
• US7399868B2
  申请人：——

  公开号：US7399868B2

  公开（公告）日：2008-07-15
• [EN] 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS<br/>[FR] 4-(HETEROARYL-METHYL ET HETEROARYL-METHYL SUBSTITUE)-IMIDAZOLE-2-THIONES UTILISEES EN TANT QU'AGONISTES DES ALPHA2 ADRENERGIQUES
  申请人：ALLERGAN INC

  公开号：WO2006036507A1

  公开（公告）日：2006-04-06

  Compounds of formula (I) where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors. Compounds of formula (I) which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.